Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development (including related party purchases of $128 and $644 for the three months ended March 31, 2023 and 2022, respectively.) $ 75,518 $ 72,071
Selling, general and administrative (including related party purchases of $24 and $161 for the three months ended March 31, 2023 and 2022, respectively.) 24,198 22,272
Total operating expenses 99,716 94,343
Loss from operations (99,716) (94,343)
Interest and other income, net 8,400 757
Income from equity method investment 0 14,458
Gain (Loss) from change in fair value of warrants and earnout shares (22,043) 16,814
Total other income (loss), net (13,643) 32,029
Loss before income taxes (113,359) (62,314)
Income tax expense 34 5
Net loss $ (113,393) $ (62,319)
Net loss per share, basic (in dollars per share) $ (0.19) $ (0.11)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.19) $ (0.11)
Weighted average number of shares outstanding, basic (in shares) 605,184,671 579,090,606
Weighted average number of shares outstanding, diluted (in shares) 605,184,671 579,090,606